Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) Short Interest Up 8.7% in August

Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) saw a significant increase in short interest in the month of August. As of August 31st, there was short interest totalling 90,400 shares, an increase of 8.7% from the July 31st total of 83,200 shares. Approximately 1.0% of the company’s shares are short sold. Based on an average daily trading volume, of 23,400 shares, the days-to-cover ratio is presently 3.9 days.

NASDAQ:CPIX traded down $0.07 during trading hours on Friday, reaching $5.07. The company had a trading volume of 65,966 shares, compared to its average volume of 26,961. The company has a quick ratio of 1.85, a current ratio of 2.33 and a debt-to-equity ratio of 0.37. The firm has a market cap of $79.02 million, a price-to-earnings ratio of -42.25 and a beta of 0.15. The business’s 50-day simple moving average is $5.49 and its two-hundred day simple moving average is $5.87. Cumberland Pharmaceuticals has a twelve month low of $4.70 and a twelve month high of $7.00.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last posted its quarterly earnings results on Wednesday, August 14th. The specialty pharmaceutical company reported $0.07 EPS for the quarter, topping analysts’ consensus estimates of $0.05 by $0.02. The business had revenue of $11.58 million during the quarter, compared to analysts’ expectations of $12.59 million. Cumberland Pharmaceuticals had a negative net margin of 9.87% and a positive return on equity of 5.04%. As a group, equities analysts predict that Cumberland Pharmaceuticals will post 0.31 earnings per share for the current year.

In other news, Director Gordon R. Bernard sold 13,264 shares of the stock in a transaction on Wednesday, June 26th. The shares were sold at an average price of $6.31, for a total transaction of $83,695.84. Following the completion of the sale, the director now directly owns 86,319 shares in the company, valued at $544,672.89. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Gordon R. Bernard sold 4,000 shares of the stock in a transaction on Monday, June 24th. The stock was sold at an average price of $6.36, for a total transaction of $25,440.00. Following the sale, the director now owns 86,319 shares of the company’s stock, valued at $548,988.84. The disclosure for this sale can be found here. Over the last quarter, insiders have bought 4,534 shares of company stock valued at $28,179 and have sold 69,139 shares valued at $410,091. Corporate insiders own 39.38% of the company’s stock.

A number of large investors have recently bought and sold shares of CPIX. Bailard Inc. acquired a new stake in Cumberland Pharmaceuticals in the second quarter worth $92,000. Acadian Asset Management LLC grew its holdings in Cumberland Pharmaceuticals by 6.9% in the second quarter. Acadian Asset Management LLC now owns 104,498 shares of the specialty pharmaceutical company’s stock worth $665,000 after purchasing an additional 6,765 shares during the period. BlackRock Inc. grew its holdings in Cumberland Pharmaceuticals by 17.2% in the second quarter. BlackRock Inc. now owns 332,543 shares of the specialty pharmaceutical company’s stock worth $2,118,000 after purchasing an additional 48,753 shares during the period. Finally, Renaissance Technologies LLC grew its holdings in Cumberland Pharmaceuticals by 13.0% in the second quarter. Renaissance Technologies LLC now owns 441,577 shares of the specialty pharmaceutical company’s stock worth $2,813,000 after purchasing an additional 50,800 shares during the period. Institutional investors and hedge funds own 31.03% of the company’s stock.

CPIX has been the subject of several recent analyst reports. Zacks Investment Research upgraded shares of Cumberland Pharmaceuticals from a “hold” rating to a “buy” rating and set a $6.00 price objective for the company in a research report on Wednesday, August 21st. ValuEngine cut shares of Cumberland Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, September 10th.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology markets in the United States and internationally. It offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol injection for treating hyponatremia; Ethyol injection for the reduction of xerostomia; Totect injection, for emergency oncology intervention, to treat the toxic effects of anthracycline chemotherapy; and Vibativ injection, for the treatment of certain serious bacterial infections.

See Also: Growth Stocks

Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.